Ceftriaxone + TazobactamThird Party Manufacturing in India

Ceftriaxone + Tazobactam works by pairing a broad-spectrum cephalosporin with a highly potent beta-lactamase inhibitor to combat resistant bacterial infections.

Ceftriaxone acts by binding to and inhibiting penicillin-binding proteins (PBPs), which are critical for the transpeptidation stage of bacterial cell wall synthesis. This causes cell wall destabilization, osmotic lysis, and cell death. Tazobactam works as an irreversible inhibitor of class A and class C beta-lactamases, which are enzymes secreted by resistant bacteria to disable beta-lactam antibiotics. By neutralizing these enzymes, Tazobactam acts as a sacrificial shield, preserving Ceftriaxone from enzymatic hydrolysis.

Unlike Ceftriaxone alone, this combination shows superior efficacy against Extended-Spectrum Beta-Lactamase (ESBL) producing Gram-negative strains. It is a vital clinical choice for treating severe, drug-resistant hospital infections where monotherapy is likely to fail. It helps preserve the clinical utility of cephalosporins in critical care settings.

Therapeutic Uses

Ceftriaxone + Tazobactam is prescribed for the treatment of:

• Complicated Urinary Tract Infections: Treats severe UTIs and pyelonephritis caused by ESBL-producing bacteria.
• Severe Pneumonia: Manages community-acquired and nosocomial lower respiratory tract infections.
• Intra-abdominal Infections: Resolves peritonitis and abdominal abscesses.
• Sepsis: Treats life-threatening systemic bacterial infections.
• Skin and Soft Tissue Infections: Manages cellulitis, diabetic foot infections, and surgical wounds.
• Gynecological Infections: Used for pelvic inflammatory disease and endometritis.

Why Partner with a WHO-GMP Ceftriaxone + Tazobactam Manufacturer

Ceftriaxone + Tazobactam third party manufacturing in India has become increasingly critical due to rising ESBL-mediated antibiotic resistance in clinical settings. Clinicians frequently turn to this combination to treat complicated infections before resorting to carbapenems, creating a steady and robust market demand.

Partnering with a WHO-GMP contract manufacturer ensures that the product is manufactured in a specialized sterile facility. This maintains the precise stoichiometric ratio of the active ingredients, prevents contamination, and ensures reliable dissolution and potency required by hospitals, PCD franchise networks, and international procurement agencies.